217 related articles for article (PubMed ID: 30698331)
1. An in vitro study to investigate the interference of enoxaparin on plasma levels of direct oral factor Xa inhibitors measured by chromogenic assays.
Cini M; Legnani C; Testa S; Tripodi A; Cosmi B; Palareti G
Int J Lab Hematol; 2019 Jun; 41(3):309-315. PubMed ID: 30698331
[TBL] [Abstract][Full Text] [Related]
2. DOAC plasma levels measured by chromogenic anti-Xa assays and HPLC-UV in apixaban- and rivaroxaban-treated patients from the START-Register.
Cini M; Legnani C; Padrini R; Cosmi B; Dellanoce C; De Rosa G; Marcucci R; Pengo V; Poli D; Testa S; Palareti G
Int J Lab Hematol; 2020 Apr; 42(2):214-222. PubMed ID: 32039550
[TBL] [Abstract][Full Text] [Related]
3. Cross-interference of rivaroxaban and enoxaparin on Berichrom anti-Xa heparin and Biophen direct Xa inhibitor assays.
Wong WH; Kaur H; Tan CW; Lee LH; Ng HJ
Int J Lab Hematol; 2018 Aug; 40(4):e63-e65. PubMed ID: 29663719
[No Abstract] [Full Text] [Related]
4. Assessment of low plasma concentrations of apixaban in the periprocedural setting.
Lessire S; Dincq AS; Siriez R; Pochet L; Sennesael AL; Vornicu O; Hardy M; Deceuninck O; Douxfils J; Mullier F
Int J Lab Hematol; 2020 Aug; 42(4):394-402. PubMed ID: 32297711
[TBL] [Abstract][Full Text] [Related]
5. Development of new methodologies for the chromogenic estimation of betrixaban concentrations in plasma.
Siriez R; Evrard J; Dogné JM; Pochet L; Bouvy C; Lessire S; Mullier F; Douxfils J
Int J Lab Hematol; 2019 Apr; 41(2):250-261. PubMed ID: 30604921
[TBL] [Abstract][Full Text] [Related]
6. Using a low-molecular weight heparin-calibrated anti-factor Xa assay to assess the concentration of apixaban and rivaroxaban.
von Horn H; Rasmusson A; Söderblom L; Malmström RE; Antovic J
Int J Lab Hematol; 2022 Feb; 44(1):163-167. PubMed ID: 34523813
[TBL] [Abstract][Full Text] [Related]
7. Chromogenic anti-FXa assay calibrated with low molecular weight heparin in patients treated with rivaroxaban and apixaban: possibilities and limitations.
Margetić S; Ćelap I; Delić Brkljačić D; Pavlović N; Šupraha Goreta S; Kobasić I; Lovrenčić-Huzjan A; Bašić Kes V
Biochem Med (Zagreb); 2020 Feb; 30(1):010702. PubMed ID: 31839722
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the effect of the anti-Xa direct oral anticoagulants apixaban, edoxaban, and rivaroxaban on coagulation assays.
Gosselin R; Grant RP; Adcock DM
Int J Lab Hematol; 2016 Oct; 38(5):505-13. PubMed ID: 27265752
[TBL] [Abstract][Full Text] [Related]
9. Prospective cohort study on the use of low molecular weight heparin calibrated anti-Xa assay for measurement of direct oral Xa inhibitors in ex vivo patient samples.
Lim MS; Hayes R; Sharma A; Kitiponchai T; Mohamed M; Mcrae S
Pathology; 2022 Aug; 54(5):599-605. PubMed ID: 35414442
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of a Heparin-Calibrated Antifactor Xa Assay for Measuring the Anticoagulant Effect of Oral Direct Xa Inhibitors.
Beyer J; Trujillo T; Fisher S; Ko A; Lind SE; Kiser TH
Clin Appl Thromb Hemost; 2016 Jul; 22(5):423-8. PubMed ID: 26842561
[TBL] [Abstract][Full Text] [Related]
11. Anti-Xa Oral Anticoagulant Plasma Concentration Assay in Real Life: Rivaroxaban and Apixaban Quantification in Emergency With LMWH Calibrator.
Billoir P; Barbay V; Joly LM; Fresel M; Chrétien MH; Le Cam Duchez V
Ann Pharmacother; 2019 Apr; 53(4):341-347. PubMed ID: 30378443
[TBL] [Abstract][Full Text] [Related]
12. Effects of the oral, direct factor Xa inhibitor edoxaban on routine coagulation assays, lupus anticoagulant and anti-Xa assays.
Hillarp A; Strandberg K; Baghaei F; Fagerberg Blixter I; Gustafsson KM; Lindahl TL
Scand J Clin Lab Invest; 2018; 78(7-8):575-583. PubMed ID: 30278787
[TBL] [Abstract][Full Text] [Related]
13. Preliminary report: Measurement of apixaban and rivaroxaban in plasma from bleeding patients.
Jensen KOF; Hansen SH; Goetze JP; Jesting A; Stensballe J; Hansen H
Eur J Haematol; 2017 Nov; 99(5):431-436. PubMed ID: 28833682
[TBL] [Abstract][Full Text] [Related]
14. Limitations of Specific Coagulation Tests for Direct Oral Anticoagulants: A Critical Analysis.
Ebner M; Birschmann I; Peter A; Härtig F; Spencer C; Kuhn J; Rupp A; Blumenstock G; Zuern CS; Ziemann U; Poli S
J Am Heart Assoc; 2018 Oct; 7(19):e009807. PubMed ID: 30371316
[TBL] [Abstract][Full Text] [Related]
15. Lupus anticoagulant diagnosis in patients receiving direct oral FXa inhibitors at trough levels: A real-life study.
Gay J; Duchemin J; Imarazene M; Fontenay M; Jourdi G
Int J Lab Hematol; 2019 Dec; 41(6):738-744. PubMed ID: 31487115
[TBL] [Abstract][Full Text] [Related]
16. Anti-factor IIa (FIIa) heparin assay for patients on direct factor Xa (FXa) inhibitors.
Stuart M; Johnson L; Hanigan S; Pipe SW; Li SH
J Thromb Haemost; 2020 Jul; 18(7):1653-1660. PubMed ID: 32216028
[TBL] [Abstract][Full Text] [Related]
17. Can an anti-Xa assay for low-molecular-weight heparin be used to assess the presence of rivaroxaban?
Yates SG; Smith S; Tharpe W; Shen YM; Sarode R
Transfus Apher Sci; 2016 Oct; 55(2):212-215. PubMed ID: 27377884
[TBL] [Abstract][Full Text] [Related]
18. Accuracy and consistency of anti-Xa activity measurement for determination of rivaroxaban plasma levels.
Studt JD; Alberio L; Angelillo-Scherrer A; Asmis LM; Fontana P; Korte W; Mendez A; Schmid P; Stricker H; Tsakiris DA; Wuillemin WA; Nagler M
J Thromb Haemost; 2017 Aug; 15(8):1576-1583. PubMed ID: 28574652
[TBL] [Abstract][Full Text] [Related]
19. Practical Nomogram Predicting Apixaban or Rivaroxaban Concentrations from Low-Molecular-Weight Heparin Anti-Xa Values: Special Interest in Acute Ischemic Stroke Patients.
Brakta C; Stépanian A; Reiner P; Delrue M; Mazighi M; Curis E; Siguret V
J Stroke; 2023 Jan; 25(1):126-131. PubMed ID: 36592965
[TBL] [Abstract][Full Text] [Related]
20. [Interference of oral anti-Xa anticoagulants during monitoring of unfractionated heparin treatments: practical and future attitudes].
Melicine S; Maucorps L; Eschwège V; Carré J; Helley D; Gouin-Thibault I; Gendron N; Nédélec-Gac F; Mauge L
Ann Biol Clin (Paris); 2024 Jun; 82(2):129-138. PubMed ID: 38832688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
